Related references
Note: Only part of the references are listed.Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Habib Yaribeygi et al.
DRUG DISCOVERY TODAY (2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps
Bernadette Thomas
CURRENT DIABETES REPORTS (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
Vjera Nincevic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals
Francesca Viazzi et al.
JOURNAL OF NEPHROLOGY (2019)
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition
Sandor Koszegi et al.
JOURNAL OF PHYSIOLOGY-LONDON (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials
Maria-Eleni Alexandrou et al.
JOURNAL OF HYPERTENSION (2019)
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
T. Cooper Woods et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Update on Diabetic Nephropathy: Core Curriculum 2018
Kausik Umanath et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension: a real-life observational study
Francesca Viazzi et al.
JOURNAL OF HYPERTENSION (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials
Srinivasan Beddhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Antihypertensive treatment and renal protection: Is there a J-curve relationship?
Francesca Viazzi et al.
JOURNAL OF CLINICAL HYPERTENSION (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Bryan Williams et al.
JOURNAL OF HYPERTENSION (2018)
Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes
Francesca Viazzi et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
Jens Oellgaard et al.
KIDNEY INTERNATIONAL (2017)
Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus
Francesca Viazzi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Li-Jing Sun et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Diabetic nephropathy: landmark clinical trials and tribulations
Gary C. W. Chan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis
Francesca Viazzi et al.
JOURNAL OF HYPERTENSION (2016)
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Dena Ettehad et al.
LANCET (2016)
Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials
Gianluigi Savarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes
Salvatore De Cosmo et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Aldosterone antagonists for preventing the progression of chronic kidney disease
Davide Bolignano et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD
Sandra J. Taler et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat
Bruno S. Pessoa et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
E. Imai et al.
DIABETOLOGIA (2011)
Clinical significance of nonalbuminuric renal impairment in type 2 diabetes
Giuseppe Penno et al.
JOURNAL OF HYPERTENSION (2011)
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Juan F. Navarro-Gonzalez et al.
NATURE REVIEWS NEPHROLOGY (2011)
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DIABETIC NEPHROPATHY Diabetic nephropathy-challenges in pathologic classification
Paola Fioretto et al.
NATURE REVIEWS NEPHROLOGY (2010)
Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes Three Randomized Trials
Rudy Bilous et al.
ANNALS OF INTERNAL MEDICINE (2009)
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
Bastiaan E. de Galan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes.
Michael Mauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial
G. L. Bakris et al.
KIDNEY INTERNATIONAL (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel et al.
LANCET (2007)
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
Hirofumi Makino et al.
DIABETES CARE (2007)
Albuminuria: A target for treatment of type 2 diabetic nephropathy
Dick de Zeeuw
SEMINARS IN NEPHROLOGY (2007)
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Sang-Youb Han et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
RC Atkins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
G Fujisawa et al.
KIDNEY INTERNATIONAL (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
AH Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preventing microalbuminuria in type 2 diabetes
P Ruggenenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
P Jacobsen et al.
KIDNEY INTERNATIONAL (2003)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
P Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
AI Adler et al.
KIDNEY INTERNATIONAL (2003)
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect
G Viberti et al.
CIRCULATION (2002)
Aldosterone in progressive renal disease
TH Hostetter et al.
SEMINARS IN NEPHROLOGY (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
